OTCPK:LBLTF (USA) Also trade in: Canada Germany

Lattice Biologics Ltd

$ 0.02 0 (-20%)
On watch
Volume: 18,000 Avg Vol (1m): 8,572
Market Cap $: 2.15 Mil Enterprise Value $: 4.23 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -0.12
Net Current Asset Value -0.07
Tangible Book -0.06
Projected FCF -0.13
Median P/S Value 0.03
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Equity-to-Asset -1.66
Equity-to-Asset range over the past 10 years
Min: -1.76, Med: -1.29, Max: -0.72
Current: -1.66
-1.76
-0.72
Debt-to-Equity -0.38
Debt-to-Equity range over the past 10 years
Min: -0.96, Med: -0.52, Max: 0.32
Current: -0.38
-0.96
0.32
Debt-to-EBITDA -10.47
Debt-to-EBITDA range over the past 10 years
Min: -10.47, Med: -1.69, Max: -0.45
Current: -10.47
-10.47
-0.45
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.44
DISTRESS
GREY
SAFE
Beneish M-Score -3.79
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 15.98%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -53.85
Operating Margin range over the past 10 years
Min: -128.48, Med: -102.74, Max: -53.85
Current: -53.85
-128.48
-53.85
Net Margin % -54.40
Net Margin range over the past 10 years
Min: -207.83, Med: -106.58, Max: -54.4
Current: -54.4
-207.83
-54.4
ROA % -29.56
ROA range over the past 10 years
Min: -1653.27, Med: -70.62, Max: -0.87
Current: -29.56
-1653.27
-0.87
ROC (Joel Greenblatt) % -98.66
ROC (Joel Greenblatt) range over the past 10 years
Min: -4173.3, Med: -110.4, Max: -0.91
Current: -98.66
-4173.3
-0.91
3-Year Total EBITDA Growth Rate -7.10
3-Year EBITDA Growth Rate range over the past 10 years
Min: -70.2, Med: 14.1, Max: 71.5
Current: 70
-70.2
71.5
3-Year EPS w/o NRI Growth Rate 64.70
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -71.8, Med: 14.2, Max: 72.2
Current: 64.7
-71.8
72.2

» LBLTF's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:LBLTF

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Devices » Medical Devices    NAICS : 621511    SIC : 8681
Compare OTCPK:VICA XSAT:POLAR NAS:SINT ASX:NTI XSAT:QUICK XPAR:ALSGD NGM:CMH XPAR:ALSPW XSAT:SDET BOM:530427 OTCPK:ESMC OTCPK:EQUR BOM:512487 ASX:ADR OTCPK:MODD OTCPK:GTHP OTCPK:RSLS OTCPK:VASO XSAT:EMOT OTCPK:VYCO
Traded in other countries LBL.Canada B5G2.Germany
Address 512 East Madison Avenue, Suite 101, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets the biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Ratios

Current vs industry vs history
Price-to-Owner-Earnings 10.00
Price-to-Owner-Earnings range over the past 10 years
Min: 1.67, Med: 7.5, Max: 21.67
Current: 10
1.67
21.67
PS Ratio 1.20
PS Ratio range over the past 10 years
Min: 0.56, Med: 1.9, Max: 7.06
Current: 1.2
0.56
7.06
Price-to-Free-Cash-Flow 15.00
Price-to-Free-Cash-Flow range over the past 10 years
Min: 10, Med: 15, Max: 20
Current: 15
10
20
Price-to-Operating-Cash-Flow 6.00
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.33, Med: 6.67, Max: 13.33
Current: 6
3.33
13.33
EV-to-EBIT -9.75
EV-to-EBIT range over the past 10 years
Min: -11.4, Med: -2.1, Max: 610
Current: -9.75
-11.4
610
EV-to-EBITDA -21.18
EV-to-EBITDA range over the past 10 years
Min: -24.8, Med: -2.2, Max: 40.9
Current: -21.18
-24.8
40.9
EV-to-Revenue 2.47
EV-to-Revenue range over the past 10 years
Min: 2.1, Med: 3.5, Max: 9.5
Current: 2.47
2.1
9.5
Current Ratio 0.26
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.36, Max: 160.67
Current: 0.26
0.01
160.67
Quick Ratio 0.07
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.24, Max: 160.67
Current: 0.07
0.01
160.67
Days Inventory 787.00
Days Inventory range over the past 10 years
Min: 135.47, Med: 353.08, Max: 958.56
Current: 787
135.47
958.56
Days Sales Outstanding 103.71
Days Sales Outstanding range over the past 10 years
Min: 28.92, Med: 40.96, Max: 103.71
Current: 103.71
28.92
103.71
Days Payable 1.00
Days Payable range over the past 10 years
Min: 1, Med: 423.93, Max: 1740.59
Current: 1
1
1740.59

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -259.00
3-Year Share Buyback Rate range over the past 10 years
Min: -259, Med: -30.6, Max: 0
Current: -259
-259
0

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.60
Price-to-Median-PS-Value range over the past 10 years
Min: 0.51, Med: 1, Max: 3
Current: 0.6
0.51
3
Earnings Yield (Joel Greenblatt) % -10.26
Earnings Yield (Greenblatt) range over the past 10 years
Min: -94.7, Med: -22.3, Max: 14.7
Current: -10.26
-94.7
14.7

More Statistics

Revenue (TTM) (Mil) $ 1.69
EPS (TTM) $ -0.01
Beta 8.87
Volatility % 659.91
52-Week Range $ 0 - 0.06
Shares Outstanding (Mil) 93.46

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y